Nathan Weinstein
Stock Analyst at Aegis Capital
(0.27)
# 4,225
Out of 4,910 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.36 | +5,782.35% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.69 | +2,070.14% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.74 | +716.33% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $1.00 | +3,410.53% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.28 | +163.16% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.30 | +1,204.35% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $7.89 | +26.74% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $21.00 | +133.33% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.37 | +10,848.91% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $5.57 | +38,679.17% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.10 | +2,639.73% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $1.36 | +635.29% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $64.85 | +146.72% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $25.93 | +115.97% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $3.88 | +595.88% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.73 | +4,668.39% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.93 | +521.76% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $11.49 | +552.74% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $3.53 | +2,392.92% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.73 | +6,493.41% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.40 | +2,968.18% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.95 | +101.44% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $15.55 | +1,315.25% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $3.38 | +151.48% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.36
Upside: +5,782.35%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.69
Upside: +2,070.14%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.74
Upside: +716.33%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $1.00
Upside: +3,410.53%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.28
Upside: +163.16%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.30
Upside: +1,204.35%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $7.89
Upside: +26.74%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $21.00
Upside: +133.33%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.37
Upside: +10,848.91%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $5.57
Upside: +38,679.17%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.10
Upside: +2,639.73%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $1.36
Upside: +635.29%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $64.85
Upside: +146.72%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $25.93
Upside: +115.97%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $3.88
Upside: +595.88%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.73
Upside: +4,668.39%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.93
Upside: +521.76%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $11.49
Upside: +552.74%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $3.53
Upside: +2,392.92%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.73
Upside: +6,493.41%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.40
Upside: +2,968.18%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $6.95
Upside: +101.44%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $15.55
Upside: +1,315.25%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $3.38
Upside: +151.48%